Biogen revises label for new Alzheimer's drug, limiting use to those with mild dementia

Drugmaker Biogen revised the label for its new Alzheimer's disease drug aducanumab, effectively recommending its use only in patients with mild cognitive impairment or dementia, the company confirmed Thursday.

Source: Health News - UPI.com - July 8, 2021 Category: Consumer Health News Source Type: news